# EDGAR Filing Document

**Accession Number:** 0001699737
**File Stem:** 0001699737-25-000022
**Filing Date:** 2025-11
**Character Count:** 21401
**Document Hash:** d03b5fbbdd1c09abbb56cd2b6f10d6f2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001699737-25-000022.hdr.sgml**: 20251119

**ACCESSION NUMBER**: 0001699737-25-000022

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20251119

**DATE AS OF CHANGE**: 20251119

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Inventiva S.A.
- **CENTRAL INDEX KEY:** 0001756594
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** I0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-91576
- **FILM NUMBER:** 251500791

**BUSINESS ADDRESS:**
- **STREET 1:** 50 RUE DE DIJON
- **CITY:** DAIX
- **STATE:** I0
- **ZIP:** 21121
- **BUSINESS PHONE:** 33380447500

**MAIL ADDRESS:**
- **STREET 1:** 50 RUE DE DIJON
- **CITY:** DAIX
- **STATE:** I0
- **ZIP:** 21121
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Samsara BioCapital, L.P.
- **CENTRAL INDEX KEY:** 0001699737

**ORGANIZATION NAME:**
- **EIN:** 813958301
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 628 MIDDLEFIELD ROAD
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94301
- **BUSINESS PHONE:** (650) 285-4270

**MAIL ADDRESS:**
- **STREET 1:** 628 MIDDLEFIELD ROAD
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94301

## Exhibit 99.1

EXHIBIT 99.1

JOINT FILING AGREEMENT

We, the undersigned, hereby express our agreement that the Schedule 13D (or any amendments thereto) relating to the Ordinary Shares of Inventiva S.A. is filed on behalf of each of us.

Dated: November 19, 2025

**Samsara BioCapital, L.P.**

By:

Samsara BioCapital GP, LLC

its

General Partner

By:

<u>/s/ Srinivas Akkaraju</u>

Name: Srinivas Akkaraju

Title: Managing Member

**Samsara BioCapital GP, LLC**

By:

<u>/s/ Srinivas Akkaraju</u>

Name: Srinivas Akkaraju

Title: Managing Member

**Samsara Opportunity Fund, L.P.**

By:

Samsara Opportunity Fund GP, LLC

its

General Partner

By:

<u>/s/ Srinivas Akkaraju</u>

Name: Srinivas Akkaraju

Title: Managing Member

**Samsara Opportunity Fund GP, LLC**

By:

<u>/s/ Srinivas Akkaraju</u>

Name: Srinivas Akkaraju

Title: Managing Member

**Srinivas Akkaraju**

<u>/s/ Srinivas Akkaraju</u> 

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 1)**

**Inventiva S.A.**

*(Name of Issuer)*

**Ordinary shares, nominal value (euro) 0.01 per share**

*(Title of Class of Securities)*

**46124U107**

*(CUSIP Number)*

**Abrar Hussain**<br>Samsara BioCapital GP, LLC<br>628 Middlefield Road<br>Palo Alto CA 94301<br>(650) 285-4270

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**11/17/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **46124U107** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Samsara BioCapital, L.P.** | Name of reporting person<br>**Samsara BioCapital, L.P.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**8345389.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**8345389.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**8345389.00** | Aggregate amount beneficially owned by each reporting person<br>**8345389.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**4.5%** | Percent of class represented by amount in Row (11)<br>**4.5%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** Note:  There is no CUSIP number assigned to the Ordinary Shares. The CUSIP Number 46124U107 has been assigned to the American Depositary Shares ("ADS") of the Issuer, which are quoted on the Nasdaq Global Market under the symbol "IVA". Each ADS represents 1 Ordinary Share.

| **CUSIP No.** | **46124U107** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Samsara BioCapital GP, LLC** | Name of reporting person<br>**Samsara BioCapital GP, LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**8345389.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**8345389.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**8345389.00** | Aggregate amount beneficially owned by each reporting person<br>**8345389.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**4.5%** | Percent of class represented by amount in Row (11)<br>**4.5%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

| **CUSIP No.** | **46124U107** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Samsara Opportunity Fund, L.P.** | Name of reporting person<br>**Samsara Opportunity Fund, L.P.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**5194805.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**5194805.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**5194805.00** | Aggregate amount beneficially owned by each reporting person<br>**5194805.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**2.8%** | Percent of class represented by amount in Row (11)<br>**2.8%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

| **CUSIP No.** | **46124U107** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Samsara Opportunity Fund GP, LLC** | Name of reporting person<br>**Samsara Opportunity Fund GP, LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**5194805.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**5194805.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**5194805.00** | Aggregate amount beneficially owned by each reporting person<br>**5194805.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**2.8%** | Percent of class represented by amount in Row (11)<br>**2.8%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

| **CUSIP No.** | **46124U107** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Srinivas Akkaraju** | Name of reporting person<br>**Srinivas Akkaraju** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**13540194.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**13540194.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**13540194.00** | Aggregate amount beneficially owned by each reporting person<br>**13540194.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**7.4%** | Percent of class represented by amount in Row (11)<br>**7.4%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Ordinary shares, nominal value (euro) 0.01 per share

**(b) Name of Issuer:**
Inventiva S.A.

**(c) Address of Issuer's Principal Executive Offices:**
50 rue de Dijon, Daix, I0, 21121

This Amendment No. 1 (this "Amendment No. 1" or this "Schedule 13D/A") amends and supplements the statement on Schedule 13D originally filed with the Securities and Exchange Commission (the "SEC") on October 21, 2025 (the "Statement") by Samsara LP, Samsara GP and Dr. Akkaraju. Unless otherwise defined herein, capitalized terms used in this Amendment No. 1 shall have the meanings ascribed to them in the Statement. Unless amended or supplemented below, the information in the Statement remains unchanged.

**Item 5. Interest in Securities of the Issuer**

**(a)**
Rows 11 and 13 of each Reporting Person's cover page to this Schedule 13D/A set forth the aggregate number of Ordinary Shares and percentages of the outstanding Ordinary Shares beneficially owned by such Reporting Person and are incorporated by reference. The percentage set forth in each row 13 is based upon 183,956,467 Ordinary Shares outstanding as of November 17, 2025 upon the closing of the November 2025 Offering, as reported in the prospectus supplement filed by the Issuer with the SEC on November 13, 2025.

The Reporting Persons' ownership of the Issuer's securities consists of (i) 8,345,389 Ordinary Shares held by Samsara LP; (ii) 4,324,894 Pre-funded Warrants (exercisable for up to 4,324,894 Ordinary Shares) held directly by Samsara LP; (iii) 6,637,037 Performance Warrants (exercisable for up to 5,973,333 Ordinary Shares), held by Samsara LP; and (iv) 5,194,805 Ordinary Shares represented by American Depositary Shares held by Samsara Opportunity Fund.

Samsara GP is the sole general partner of Samsara LP and Dr. Akkaraju is the managing member of Samsara GP. Each of Samsara GP and Dr. Akkaraju possesses power to direct the voting and disposition of the securities held by Samsara LP. The Pre-funded Warrants contain a provision (the "Beneficial Ownership Blockers") which precludes exercise of the Pre-funded Warrants to the extent that, following exercise, Samsara LP, together with its affiliates and other attribution parties, would own more than 4.99% of the outstanding Ordinary Shares. The exercise of the Performance Warrants is subject to the Issuer's release of topline data announcing that any key primary endpoint or key secondary endpoint of its NATiV3, with any dosage regime tested in the trial, have been met no later than June 15, 2027 (the "Triggering Milestone"). By virtue of the Beneficial Ownership Blockers and the Triggering Milestone, the Pre-funded Warrants and Performance Warrants are currently not exercisable and the Ordinary Shares issuable upon exercise of such warrants are not considered beneficially owned as of the date of this filing.

Samsara Opportunity GP is the sole general partner of Samsara Opportunity Fund and Dr. Akkaraju is the managing member of Samsara Opportunity GP.  Each of Samsara Opportunity GP and Dr. Akkaraju possesses power to direct the voting and disposition of the securities held by Samsara Opportunity Fund.

**(b)**
Rows 7 through 10 of each Reporting Person's cover page to this Schedule 13D/A set forth the number of Ordinary Shares as to which such Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition and are incorporated by reference.

**(c)**
Except as set forth below and elsewhere in this report, none of the Reporting Persons has effected any transactions with respect to the securities of the Issuer since the date of the filing of the Statement:

On October 21, 2025, Samsara LP sold 24,747 Ordinary Shares in open market transactions at prices ranging from $3.26 to $3.33 per share (a weighted-average price of $3.27 per share).

On October 22, 2025, Samsara LP sold 51,789 Ordinary Shares in open market transactions at prices ranging from $3.11 to $3.28 per share (a weighted-average price of $3.16 per share).

On October 23, 2025, Samsara LP sold 61,048 Ordinary Shares in open market transactions at prices ranging from $2.99 to $3.15 per share (a weighted-average price of $3.06 per share).

On October 29, 2025, Samsara LP exercised Pre-funded Warrants to purchase 321,031 Ordinary Shares at an exercise price of 0.01 Euro per share.

The foregoing Ordinary Shares and Pre-funded Warrants were held by Samsara LP for the exclusive benefit of limited partners who had redeemed their respective interests in Samsara LP and in which neither Samsara GP nor Dr. Akkaraju had any economic interest.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Item 6 of the Statement is hereby amended and supplemented as follows:

Lock-up Agreement

Each of the Issuer's executive officers and directors, including Dr. Akkaraju, have agreed, with limited exceptions, for a period of 90 days after November 13, 2025, without the prior written consent of each of Leerink Partners LLC and Piper Sandler & Co., not to (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any Ordinary Shares, including Ordinary Shares represented by American Depositary Shares, or any securities convertible into or exercisable or exchangeable for Ordinary Shares or American Depositary Shares (including, without limitation, Ordinary Shares or American Depositary Shares or such other securities which may be deemed to be beneficially owned by such individual (excluding, in the case of Dr. Akkaraju, securities held by Samsara LP) in accordance with the rules and regulations of the SEC and securities which may be issued upon exercise of a stock option or warrant) or publicly disclose the intention to make any offer, sale pledge or disposition or (2) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of any Ordinary Shares or American Depositary Shares or such other securities.

The foregoing description is not complete and is qualified in its entirety by reference to the full text of the form of the lock-up agreement filed herewith as Exhibit 99.2 and incorporated by reference herein.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Samsara BioCapital, L.P.

**Signature:** /s/ Srinivas Akkaraju

**Name/Title:** By Samsara BioCapital GP, LLC, its General Partner, By Srinivas Akkaraju, Managing Member

**Date:** 11/19/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Samsara BioCapital GP, LLC

**Signature:** /s/ Srinivas Akkaraju

**Name/Title:** By Srinivas Akkaraju, Managing Member

**Date:** 11/19/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Samsara Opportunity Fund, L.P.

**Signature:** /s/ Srinivas Akkaraju

**Name/Title:** By Samsara Opportunity Fund GP, LLC, its General Partner, By Srinivas Akkaraju, Managing Member

**Date:** 11/19/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Samsara Opportunity Fund GP, LLC

**Signature:** /s/ Srinivas Akkaraju

**Name/Title:** By Srinivas Akkaraju, Managing Member

**Date:** 11/19/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Srinivas Akkaraju

**Signature:** /s/ Srinivas Akkaraju

**Name/Title:** Srinivas Akkaraju

**Date:** 11/19/2025